Literature DB >> 15848306

Complex pulmonary aspergilloma treated with single stage cavernostomy and myoplasty.

Cengiz Gebitekin1, A Sami Bayram, Selcuk Akin.   

Abstract

OBJECTIVE: Complex pulmonary aspergilloma (CPA) following pulmonary tuberculosis may lead to massive and fatal hemoptysis. Pulmonary resection, as initial therapy, carries high morbidity and mortality. Resection is contraindicated in patients with compromised lung function (FEV1<40%) and in those with bilateral disease. We reviewed the results of patients undergoing single stage cavernostomy and myoplasty as an alternative therapy in patients with normal and compromised lung function.
METHODS: Patients suffering from recurrent massive hemoptysis (600ml/24h or >150ml/h) due to CPA were selected for single stage cavernostomy and myoplasty. We performed rib resection, cavernostomy, closure of the bronchial openings and total/partial obliteration of the cavity with a muscle flap as a single stage technique in patients with CPA regardless of pulmonary function or bilateral disease. Patients began oral Itracanozole two weeks prior to surgery and continued for 3 months post-operatively.
RESULTS: Three women and four men (median age 38 years; range 24-59 years) with CPA were evaluated. Four patients had either bilateral disease or compromised lung function. Pectoralis major muscle was used for the myoplasty in five and trapezius or latissimus dorsi in the other two patients. The median number of bronchial fistulae closed during the surgery was six (range 2-12). Blood loss was minimal (median 227ml). Two patients underwent successful re-exploration for significant air leak. The median hospital stay was 9 days (6-27days). Six patients are alive and hemoptysis free (median follow-up 57.2 months).
CONCLUSIONS: Cavernostomy and myoplasty as a single stage technique is safe and reliable in the management of patients with complex pulmonary aspergilloma. Morbidity is low even in patients with compromised lung function or bilateral disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848306     DOI: 10.1016/j.ejcts.2005.02.008

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  [Lung cavities, mycetomas and hemoptysis].

Authors:  Wolfgang Domej; Josef Hermann; Robert Krause; Martin Wehrschütz; Alfred Maier; Erich Flögel
Journal:  Wien Med Wochenschr       Date:  2007

2.  Lung resection in pulmonary aspergilloma: experience of a Moroccan center.

Authors:  Mohammed Massine El Hammoumi; Omar Slaoui; Fayçal El Oueriachi; El Hassane Kabiri
Journal:  BMC Surg       Date:  2015-10-16       Impact factor: 2.102

3.  The effects of antifungal therapy on the recurrence of aspergillus infection after pulmonary aspergilloma resection: a study protocol for a single-center, prospective, non-blind, randomized, 24-month, parallel group study.

Authors:  Xianqiu Chen; Yiming Zhou; Lijuan Zhang; Jinfu Xu; Shuo Liang
Journal:  BMC Pulm Med       Date:  2021-10-29       Impact factor: 3.317

4.  [Severity Factors of Pulmonary Aspergilloma in the Surgical Intensive Care Unit of Joseph Ravoahangy Andrianavalona Hospital, Antananarivo, Madagascar].

Authors:  N N M Razafimanjato; J M Rakotoson; M Ravoatrarilandy; R L Andrianasolo; A T Rajaonera; N E Raveloson; H J L Rakotovao
Journal:  Med Trop Sante Int       Date:  2021-02-18

5.  Monaldi cavernostomy for lung aspergillosis: A case report.

Authors:  Cornel Petreanu; Alina Croitoru; Alexandru Gibu; Alexandru Zariosu; Nicolae Bacalbasa; Irina Balescu; Camelia Diaconu; Ovidiu Stiru; Mihai Dimitriu; Dragos Cretoiu; Cornel Savu
Journal:  Exp Ther Med       Date:  2021-07-06       Impact factor: 2.447

6.  Outcomes of surgery for different types of chronic pulmonary aspergillosis: results from a single-center, retrospective cohort study.

Authors:  ChangMing Shen; GaoFeng Qiao; Cheng Wang; Feng Jin; YunZeng Zhang
Journal:  BMC Pulm Med       Date:  2022-01-19       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.